Resveratrol in the management of obesity-related fatty liver disease: a randomized, double-blind, placebo-controlled clinical trial
Event details
| Date | 18.12.2012 |
| Hour | 10:00 › 11:00 |
| Speaker |
Véronique CHACHAY Accredited Practising Dietitian, MSc Nutrition and Dietetics, PhD candidate The University of Queensland Diamantina Institute -Metabolic medicine group Research wing, Princess Alexandra Hospital, Ipswich Road Brisbane, Qld 4102, Australia |
| Location | |
| Category | Conferences - Seminars |
We investigated the efficacy of nutraceutical resveratrol on hepatic and cardiometabolic dysregulation in 20 overweight/obese men with non-alcoholic fatty liver disease (NAFLD), randomized to either 3000mg resveratrol (1500mg b.d.) or placebo daily for 8 weeks.
Primary outcome: Peripheral insulin resistance, (euglycemic-hyperinsulinemic clamp).
Secondary outcomes: Hepatic triglycerides content and abdominal adipose tissue topography (magnetic resonance spectroscopy and imaging); plasma adiponectin (total and high molecular-weight); oxidative-stress and antioxidant capacity (isoprostanes, TAC, GPX, FRAP, SOD); inflammatory and liver biochemistry.
Conclusion: Despite demonstrated prevention of NAFLD in animal models, nutraceutical trans-resveratrol at this dosage, over 8 weeks, did not demonstrate apparent clinical benefit in patients with well established NAFLD.
Primary outcome: Peripheral insulin resistance, (euglycemic-hyperinsulinemic clamp).
Secondary outcomes: Hepatic triglycerides content and abdominal adipose tissue topography (magnetic resonance spectroscopy and imaging); plasma adiponectin (total and high molecular-weight); oxidative-stress and antioxidant capacity (isoprostanes, TAC, GPX, FRAP, SOD); inflammatory and liver biochemistry.
Conclusion: Despite demonstrated prevention of NAFLD in animal models, nutraceutical trans-resveratrol at this dosage, over 8 weeks, did not demonstrate apparent clinical benefit in patients with well established NAFLD.
Practical information
- General public
- Free
Organizer
- Kristina Schoonjans and Johan Auwerx
Contact
- Johan Auwerx